ECSP003590A - Compuestos calcioliticos - Google Patents

Compuestos calcioliticos

Info

Publication number
ECSP003590A
ECSP003590A EC2000003590A ECSP003590A ECSP003590A EC SP003590 A ECSP003590 A EC SP003590A EC 2000003590 A EC2000003590 A EC 2000003590A EC SP003590 A ECSP003590 A EC SP003590A EC SP003590 A ECSP003590 A EC SP003590A
Authority
EC
Ecuador
Prior art keywords
calciolitic
compounds
bones
disorders
new methods
Prior art date
Application number
EC2000003590A
Other languages
English (en)
Inventor
Maxine Gowen
Larry S Suva
John Fox
George B Stroup
Edward F Nemeth
Original Assignee
Smithkline Beecham Corp
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Nps Pharma Inc filed Critical Smithkline Beecham Corp
Publication of ECSP003590A publication Critical patent/ECSP003590A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se proporcionan nuevos métodos para tratar enfermedades o transtornos de los huesos.
EC2000003590A 1999-07-31 2000-07-28 Compuestos calcioliticos ECSP003590A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US14677899P 1999-07-31 1999-07-31

Publications (1)

Publication Number Publication Date
ECSP003590A true ECSP003590A (es) 2002-02-25

Family

ID=22518969

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2000003590A ECSP003590A (es) 1999-07-31 2000-07-28 Compuestos calcioliticos

Country Status (21)

Country Link
EP (1) EP1200076A4 (es)
JP (1) JP2003505502A (es)
KR (1) KR20020016928A (es)
CN (1) CN1367687A (es)
AU (1) AU764716B2 (es)
BR (1) BR0012921A (es)
CA (1) CA2380081A1 (es)
CO (1) CO5180628A1 (es)
CZ (1) CZ2002360A3 (es)
EC (1) ECSP003590A (es)
HK (1) HK1046238A1 (es)
HU (1) HUP0202167A3 (es)
IL (1) IL147875A0 (es)
MX (1) MXPA02001204A (es)
NO (1) NO20020466L (es)
PE (1) PE20010459A1 (es)
PL (1) PL353318A1 (es)
TR (1) TR200200278T2 (es)
UY (1) UY26265A1 (es)
WO (1) WO2001008673A1 (es)
ZA (1) ZA200200784B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR030684A1 (es) * 2000-01-24 2003-09-03 Smithkline Beecham Corp Compuestos calciliticos, uso de dichos compuestos en la manufactura de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
US20030018203A1 (en) 2002-07-17 2003-01-23 Largo Maria Amparo Calcilytic compounds
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
TWI316511B (en) 2002-11-26 2009-11-01 Smithkline Beecham Corp Calcilytic compounds
US7205322B2 (en) 2003-02-12 2007-04-17 Bristol-Myers Squibb Company Thiazolidine compounds as calcium sensing receptor modulators
US7265145B2 (en) 2003-05-28 2007-09-04 Bristol-Myers Squibb Company Substituted piperidines and pyrrolidines as calcium sensing receptor modulators and method
TW200845956A (en) * 2006-12-18 2008-12-01 Smithkline Beecham Corp Calcilytic compounds
WO2013098588A1 (en) * 2011-12-27 2013-07-04 Ubaldo Armato Use of calcilytic drugs as a pharmacological approach to the treatment and prevention of alzheimer's disease, alzheimer's disease-related disorders, and down's syndrome neuropathies
GB201217330D0 (en) 2012-09-28 2012-11-14 Univ Cardiff Therapeutic for treating inflammatory lung disorders
CN108420814A (zh) * 2017-02-15 2018-08-21 四川大学 一种nps-2143用于抗菌的新用途
CN116173187B (zh) * 2023-03-14 2024-05-10 哈尔滨医科大学 降钙素在制备防治支架内再狭窄药物中的应用、药物涂层支架及制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU726659B2 (en) * 1996-04-09 2000-11-16 Nps Pharmaceuticals, Inc. Calcilytic compounds
AR018177A1 (es) * 1998-04-08 2001-10-31 Smithkline Beecham Corp Compuestos calciliticos, una composicion farmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento.
AR014975A1 (es) * 1998-04-08 2001-04-11 Nps Pharma Inc Compuestos calciliticos, una composicion farmaceutica que los comprende, y el uso de los mismos para la fabricacion de un medicamento

Also Published As

Publication number Publication date
HUP0202167A3 (en) 2006-07-28
ZA200200784B (en) 2003-01-29
UY26265A1 (es) 2001-03-16
NO20020466L (no) 2002-03-20
CA2380081A1 (en) 2001-02-08
IL147875A0 (en) 2002-08-14
KR20020016928A (ko) 2002-03-06
EP1200076A4 (en) 2005-02-09
CO5180628A1 (es) 2002-07-30
HUP0202167A2 (en) 2002-10-28
AU6504100A (en) 2001-02-19
WO2001008673A1 (en) 2001-02-08
EP1200076A1 (en) 2002-05-02
TR200200278T2 (tr) 2002-06-21
HK1046238A1 (zh) 2003-01-03
CN1367687A (zh) 2002-09-04
PL353318A1 (en) 2003-11-17
NO20020466D0 (no) 2002-01-29
PE20010459A1 (es) 2001-06-11
BR0012921A (pt) 2002-06-18
AU764716B2 (en) 2003-08-28
JP2003505502A (ja) 2003-02-12
CZ2002360A3 (cs) 2002-10-16
MXPA02001204A (es) 2004-05-21

Similar Documents

Publication Publication Date Title
DK2052714T3 (da) Topisk gel-fremføringssystem til behandling af hudlidelser
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
PT967214E (pt) Formulacoes intranasais para o tratamento de desordens sexuais
DK1206474T3 (da) Sulfonylphenylpyrazolforbindelser anvendelige som cox-2-inhibitorer
CU23029A3 (es) Analogos sustituidos del benzopirano para el tratamiento de la inflamacion
UY26130A1 (es) Compuestos para tratar la obesidad
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
SE9901077D0 (sv) Novel use
ECSP003590A (es) Compuestos calcioliticos
NO20014241D0 (no) C16-umettede FP-selektive prostaglandinanaloger
SE9801494D0 (sv) Novel use
YU60101A (sh) Derivati rezorcinola
PT983275E (pt) Novos derivados do triptolido vantajosos para o tratamento de doencas autoimunes
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
IS5951A (is) 5HT1 mótlyf fyrir meðferð gegn þunglyndi
BRPI0408117A (pt) compostos heterocìclicos bifuncionais e métodos de produção e uso dos mesmos
TR200002203T2 (tr) Lemfotoksin (LT) sentezlenme yolunun inhibitörleri kullanılarak foliküler lemfomaların tedavisi.
AR022321A1 (es) Derivados de anticonvulsivo utiles para el tratamiento de la migrana transformada
NO20012106L (no) Middel for behandling av forstyrrelser i benmetabolismen
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
ATE428429T1 (de) Prostaglandine zur behandlung von lichtstrahlung erzeugten augenerkrankungen wie photoretinitis
MX9700624A (es) Azolidinonas de imidazopiridina.
ES2165233T3 (es) Empleo de 1-fosfato de esfingosina, derivados de 1-fosfato de esfingosina y/o sus mezclas para el tratamiento de enfermedades cutaneas inflamatorias.